# US 2012/0237976 A1 · Mammalian expression vectors and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0237976 A1
- Document ID: US20120237976A1
- Status: Published application
- Kind: A1
- Application number: 13/368,618
- Filed: 2012-02-08
- Published: 2012-09-20
- Earliest claimed: 2008-01-15
- Assignees: Abbott Laboratories
- Inventors: Chung-ming HSIEH
- Web page: https://patentgrep.com/patent/US20120237976A1

## CPC

- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- C07K 16/241: {Tumor Necrosis Factors}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/52: Constant or Fc region; Isotype
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention features nucleic acids for recombinant protein expression in mammalian cell culture. The episomal vectors of the invention promote high protein production in mammalian cells expressing the SV40 T Ag or Epstein-Barr virus nuclear antigen (e.g., COS7 or HEK293-6E cells). The methods and systems are useful, for example, in pharmaceutical drug development and cloning, especially for the production of antibodies.

## Claims

### Claim 1

An expression vector comprising:
(a) an OriP origin of replication derived from Epstein-Barr virus (EBV);
(b) an SV40 origin of replication;
(c) an insertion site for inserting a gene of interest;
(d) a promoter operably linked to the insertion site, wherein the promoter is a cytomegalovirus (CMV) promoter; and, optionally,
(e) a nucleic acid sequence encoding an antibody heavy or light chain constant region, operably linked to the insertion site.

### Claim 2 (depends on 1)

The expression vector of claim 1, wherein the gene of interest is an antibody heavy or light chain variable region.

### Claim 3 (depends on 2)

The expression vector of claim 2, wherein the antibody heavy or light chain variable region is selected from the group consisting of murine, humanized, chimeric and human.

### Claim 4 (depends on 2)

The expression vector of claim 2, wherein the antibody heavy chain variable region is the heavy chain variable region of an antibody selected from the group consisting of an anti-TNFα antibody, an anti-IL-18 antibody, and an anti-IL-12 antibody.

### Claim 5 (depends on 3)

The expression vector of claim 3, wherein the antibody light chain variable region is the light chain variable region of an antibody selected from the group consisting of an anti-TNFα antibody, an anti-IL-18 antibody, and an anti-IL-12 antibody.

### Claim 6 (depends on 1)

The expression vector of claim 1, wherein the antibody heavy chain constant region is murine or human.

### Claim 7 (depends on 1)

The expression vector of claim 1, wherein the antibody heavy constant region is selected from the group consisting of gamma 1, z, a; gamma 1, z, non-a; gamma 2, n+; gamma 2, n−; and gamma 4.

### Claim 8 (depends on 7)

The expression vector of claim 7, wherein the gamma 1, z, non-a antibody heavy chain constant region further comprises an alanine mutation at position 234 of the heavy chain constant region.

### Claim 9 (depends on 8)

The expression vector of claim 8, further comprising an alanine mutation at either position 235 or 237 of the antibody heavy chain constant region.

### Claim 10 (depends on 1)

The expression vector of claim 1, wherein the antibody light chain constant region is either a human kappa isotype or a human lambda isotype.

### Claim 11 (depends on 1)

The expression vector of claim 1, wherein the antibody heavy chain constant region is either a murine gamma 1 isotype or a murine gamma 2a isotype.

### Claim 12 (depends on 1)

The expression vector of claim 1, wherein the antibody light chain constant region is a murine kappa isotype.

### Claim 13 (depends on 1)

The expression vector of claim 1, wherein the antibody heavy chain constant region is an Fc domain.

### Claim 14 (depends on 2)

The expression vector of claim 2, wherein the heavy or light chain antibody variable region is 5′ to the insertion site.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The expression vector of claim 1, further comprising a selectable marker.

### Claim 17 (depends on 16)

The expression vector of claim 16, wherein the selectable marker is an ampicillin resistance gene.

### Claim at position 18

-20. (canceled)

### Claim 21 (depends on 1)

The expression vector of claim 1, wherein the CMV promoter comprises nucleotides 1 to 608 of SEQ ID NO: 1.

### Claim at position 20

-28. (canceled)

### Claim 29 (depends on 1)

The expression vector of claim 1, wherein the OriP origin of replication comprises nucleotides 1795 to 3545 of SEQ ID NO: 1.

### Claim at position 22

-32. (canceled)

### Claim 33 (depends on 1)

The expression vector of claim 1, wherein the SV40 origin of replication comprises nucleotides 5834 to 6140 of SEQ ID NO: 1.

### Claim at position 24

-36. (canceled)

### Claim 37 (depends on 1)

The expression vector of claim 1, wherein the expression vector comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, 27, 29, and 30.

### Claim 38 (depends on 1)

The expression vector of claim 1, wherein the expression vector is described in a Figure selected from the group consisting of FIGS. 1, 8, 10, and 11.

### Claim 39 (depends on 1)

The expression vector of claim 1, further comprising a nucleic acid sequence encoding a signal peptide.

### Claim 40 (depends on 1)

A kit comprising the vector of claim 1.

### Claim 41 (depends on 1)

A mammalian host cell comprising the vector of claim 1.

### Claim 42 (depends on 41)

The mammalian host cell of claim 41, wherein the cell is a COS cell or a human embryonic kidney (HEK) cell.

### Claim 43 (depends on 42)

The mammalian host cell of claim 42, wherein the cell is a COS7 cell.

### Claim 44 (depends on 42)

The mammalian host cell of claim 42, wherein the cell is an HEK-293-6E cell.

### Claim 45 (depends on 1)

A method for producing a recombinant protein comprising introducing expression vector of claim 1 into a mammalian host cell, culturing the mammalian host cell under suitable conditions so as to express the protein, and recovering the protein.
